Researchers Target WNT Signaling Gene Vulnerability

Weill Cornell Medicine scientists identified a way to selectively block cancer-linked WNT signaling while sparing healthy tissue in early laboratory work.

Updated on Nov. 2, 2026 in Cancer

Unlabeled glass culture flasks and a pipette rack on a steel laboratory bench in soft window light. — Weill Cornell Medicine scientists identified a genetic vulnerability that could let drugs selectively block cancer-linked WNT signaling while sparing healthy tissue. AI Illustration. Upload story photo >

Researchers at Weill Cornell Medicine identified a genetic vulnerability that could allow selective targeting of WNT signaling in cancer cells, and reported their findings in Nature Chemical Biology. An experimental compound called TDI-012804 suppressed WNT signaling and inhibited growth of cancer cells lacking TNKS1 in laboratory experiments.

Why it matters

WNT signaling is overactive in nearly all colorectal cancers and many breast, lung, liver, and prostate tumors, but past efforts to block it have damaged healthy intestine and bone tissue. A selective approach could address a long-standing barrier to treating these cancers.

The findings come from preclinical laboratory and organoid model experiments, which showed TDI-012804 inhibits TNKS2 about 30 times more strongly than TNKS1. Whether the selectivity holds in living patients and whether the compound is safe remain unknown.

The players

Weill Cornell Medicine

Weill Cornell Medicine is the medical college of Cornell University based in New York City, known for biomedical research and clinical care.

The details

Researchers used computational modeling and structural analysis to find a subtle difference in a flexible region of TNKS2, exploiting the loss of a chromosome 8 region containing the TNKS1 gene found in many cancers. Cancer cells that lose TNKS1 become increasingly dependent on TNKS2 to keep WNT signaling active, and the experimental compound TDI-012804 targets that dependence.

November 2, 2026: Findings were reported on insideprecisionmedicine.com.

Big Picture

Earlier Wnt-pathway inhibitors were limited by toxicity to healthy intestine and bone, which has kept broad WNT blockade from reaching patients. This study builds on that history by proposing selectivity between two tankyrase enzymes instead of blanket suppression.

For patients, this work does not yet change treatment options, since the compound has only been tested in laboratory and organoid models. Any future therapy would first need clinical trials to establish safety and whether it affects tissues beyond the tumor.

The takeaway

Selective targeting based on a tumor's specific genetic loss may offer a path around the toxicity that has blocked earlier WNT-pathway drugs. Readers should treat these results as early-stage science rather than a near-term treatment.